Expects to report Trilogy 1 topline results in January 2020 with topline results for Trilogy 2 still expected by the end of January 2020 LAVAL, Québec, Dec. 23, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a...
– Submission Based on Positive Pivotal HER2CLIMB Trial Results Recently Presented at the 2019 San Antonio Breast Cancer Symposium and Published in the New England Journal of Medicine – – FDA Granted Breakthrough Therapy Designation for Tucatinib in Locally Advanced or...
ATLANTA, Dec. 23, 2019 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an...
TEL AVIV, Israel, Dec. 23, 2019 /PRNewswire/ — Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology to enable the functional selection of stem cells, has received approval to initiate the trial in the U.S. to evaluate the safety and...
BUFFALO GROVE, Ill.–(BUSINESS WIRE)–Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of...
Email
Text